TFE3
MOLECULAR TARGETtranscription factor binding to IGHM enhancer 3
TFE3 (transcription factor binding to IGHM enhancer 3) is targeted by 11 compounds in the BiohacksAI evidence corpus, derived from PubMed bioassay data. Each compound is ranked by confidence score (log-normalized assay count × evidence quality).
Compounds Targeting TFE3
Ranked by bioassay confidence score (PubChem active assay count × evidence quality).
| # | Compound | Confidence | Active Assays |
|---|---|---|---|
| 1 | Luteolin 5,7,3',4'-tetrahydroxy-flavone, | 0.69 | 1 |
| 2 | Bortezomib | 0.69 | 1 |
| 3 | Camptothecin | 0.69 | 1 |
| 4 | celastrol | 0.69 | 1 |
| 5 | cycloheximide | 0.69 | 1 |
| 6 | Demecolcine | 0.69 | 1 |
| 7 | Nocodazole Nocodazole is | 0.69 | 1 |
| 8 | pictilisib | 0.69 | 1 |
| 9 | Topotecan | 0.69 | 1 |
| 10 | torin 1 | 0.69 | 1 |
| 11 | Vincristine | 0.69 | 1 |
About TFE3 as a Drug Target
TFE3 (transcription factor binding to IGHM enhancer 3) is a well-characterized molecular target in biomedical research. BiohacksAI tracks 11 compounds with documented TFE3 interaction from PubChem bioassay data, cross-referenced with PubMed clinical evidence. The confidence score reflects the log-normalized count of active PubChem assays, weighted by evidence quality from the BiohacksAI corpus.
TFE3 inhibitors, activators, and modulators are of interest in research areas including longevity, metabolic health, and neurological function. Each compound profile includes evidence score, RCT count, human study ratio, research velocity, and domain relevance.